flurbiprofen has been researched along with Acute Confusional Senile Dementia in 67 studies
Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cholinesterase inhibitors and memantine are widely used for the treatment of Alzheimer disease (AD) and other non-AD dementia worldwide." | 4.86 | [Drug therapy for Alzheimer's disease]. ( Shoji, M, 2010) |
| "Nitroflurbiprofen is a nitrosylated flurbiprofen analog under development by NicOx for the potential treatment of urinary incontinence, Alzheimer's disease (AD) and the prevention and treatment of accelerated bone resorption associated with disorders such as osteoporosis, inflammatory joint disease and Paget's disease." | 4.82 | Nitroflurbiprofen (NicOx). ( Scatena, R, 2004) |
| " The most common adverse events were diarrhoea (in seven, nine, and five patients in the 800 mg, 400 mg, and placebo groups, respectively), nausea (in seven, seven, and four patients), and dizziness (in five, nine, and four patients)." | 2.73 | Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. ( Black, SE; Hendrix, SB; Laughlin, MA; Swabb, EA; Wilcock, GK; Zavitz, KH, 2008) |
| "(R)-flurbiprofen has been generally well tolerated at high doses in clinical trials." | 2.44 | Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease. ( Geerts, H, 2007) |
| " Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset." | 2.43 | Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. ( Praticò, D; Townsend, KP, 2005) |
| "The complex pathogenesis of Alzheimer's disease (AD) calls for multitarget approach for disease management." | 1.56 | Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation. ( Cao, Z; Deng, Y; He, Y; Qiang, X; Song, Q; Tian, C; Ye, C; Zhang, L, 2020) |
| "R-flurbiprofen (R-FP) was found to offer neuroprotective effects by inhibiting mitochondrial calcium overload induced by β-amyloid peptide toxicity in Alzheimer's disease (AD)." | 1.48 | Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease. ( Ho, PC; Wong, LR, 2018) |
| "To search for multifunctional anti-Alzheimer's disease (AD) agents with good safety, the previously synthesized tacrine-flurbiprofen hybrids 1a and 1b were modified into tacrine-flurbiprofen-nitrate trihybrids 3a-h." | 1.39 | Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents. ( Chen, Y; Huang, Z; Lehmann, J; Liao, H; Peng, S; Sun, J; Zhang, Y, 2013) |
| "Similarly, amyloid plaque burden, microglia activation and aberrant cell cycle events were significantly affected by CHF5074, but not DAPT, treatment." | 1.39 | Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. ( Baldassarro, VA; Baroc, MF; Calzà, L; Fernandez, M; Ferraro, L; Giardino, L; Giuliani, A; Gusciglio, M; Imbimbo, BP; Lorenzini, L; Mangano, C; Ottonello, S; Pietrini, V; Sivilia, S; Villetti, G; Viscomi, AR, 2013) |
| "Sham treatment and flurbiprofen treatment did not affect Aβ pathology, and a low dose HCT 1026 (10 mg/kg; a nitric oxide-donating flurbiprofen analog that has additional useful properties, including a remarkable gastrointestinal safety) did not affect pathology either, however a higher dose of HCT 1026 (30 mg/kg) did reduce the Aβ load." | 1.37 | Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. ( Kadish, I; Miettinen, P; van Groen, T, 2011) |
| "Ibuprofen treatment significantly reduced microglia area in cortex and hippocampus but not beta-amyloid burden." | 1.35 | CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease. ( Cenacchi, V; Facchinetti, F; Hutter-Paier, B; Imbimbo, BP; Lanzillotta, A; Pizzi, M; Villetti, G; Volta, R; Windisch, M, 2009) |
| " Chemical and plasmatic stability of prodrugs 6a- e as well as pharmacokinetic distribution studies for the prodrugs 6b and 6d were carried out." | 1.35 | Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs. ( Barrio, JR; Bersani, S; Kepe, V; Pantò, V; Pignatello, R; Pistarà, V; Puglisi, G; Salmaso, S, 2008) |
| "Our results establish that the neurotoxicity related to the Abeta peptide can be captured in vivo by functional imaging and suggest hippocampal subregions most vulnerable to its toxic effects." | 1.34 | Imaging the Abeta-related neurotoxicity of Alzheimer disease. ( Brickman, A; Brown, TR; Lee, T; Mayeux, R; Moreno, H; Small, SA; Wu, WE, 2007) |
| "New flurbiprofen analogues were synthesized, with the aim of increasing Abeta42 inhibitory potency while removing anti-COX activity." | 1.33 | Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion. ( Bigogno, C; Biscaioli, M; Bolzoni, PT; Caruso, P; Catinella, S; Cenacchi, V; Del Giudice, E; Dondio, G; Facchinetti, F; Fontanella, L; Imbimbo, BP; Marchetti, S; Misiano, P; Moretto, N; Parini, C; Peretto, I; Puccini, P; Radaelli, S; Raveglia, LF; Riccardi, B; Rizzi, A; Rondelli, I; Villetti, G; Zandi, M, 2005) |
| "Sham treatment, flurbiprofen, and the low-dose HCT 1026 did not affect pathology; however, a higher dose of HCT 1026 reduced both A load and amount of microglial activation surrounding plaques." | 1.33 | Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. ( Kadish, I; van Groen, T, 2005) |
| " Thirteen of the NSAIDs and the enantiomers of flurbiprofen were then tested in acute dosing studies in amyloid beta protein precursor (APP) transgenic mice, and plasma and brain levels of Abeta and the drug were evaluated." | 1.32 | NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. ( Das, P; Eriksen, JL; Golde, TE; Jessing, KW; Koo, EH; McLendon, DC; Ozols, VV; Sagi, SA; Smith, TE; Weggen, S; Zavitz, KH, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 27 (40.30) | 29.6817 |
| 2010's | 36 (53.73) | 24.3611 |
| 2020's | 4 (5.97) | 2.80 |
| Authors | Studies |
|---|---|
| Peretto, I | 1 |
| Radaelli, S | 1 |
| Parini, C | 1 |
| Zandi, M | 1 |
| Raveglia, LF | 1 |
| Dondio, G | 1 |
| Fontanella, L | 1 |
| Misiano, P | 1 |
| Bigogno, C | 1 |
| Rizzi, A | 1 |
| Riccardi, B | 1 |
| Biscaioli, M | 1 |
| Marchetti, S | 1 |
| Puccini, P | 1 |
| Catinella, S | 1 |
| Rondelli, I | 1 |
| Cenacchi, V | 2 |
| Bolzoni, PT | 1 |
| Caruso, P | 1 |
| Villetti, G | 5 |
| Facchinetti, F | 3 |
| Del Giudice, E | 3 |
| Moretto, N | 1 |
| Imbimbo, BP | 11 |
| Oehlrich, D | 1 |
| Berthelot, DJ | 1 |
| Gijsen, HJ | 1 |
| Zall, A | 1 |
| Kieser, D | 1 |
| Höttecke, N | 1 |
| Naumann, EC | 1 |
| Thomaszewski, B | 1 |
| Schneider, K | 1 |
| Steinbacher, DT | 1 |
| Schubenel, R | 1 |
| Masur, S | 1 |
| Baumann, K | 1 |
| Schmidt, B | 1 |
| Chen, Y | 2 |
| Sun, J | 2 |
| Huang, Z | 1 |
| Liao, H | 2 |
| Peng, S | 2 |
| Lehmann, J | 2 |
| Zhang, Y | 3 |
| Cao, Z | 4 |
| Yang, J | 1 |
| Xu, R | 1 |
| Song, Q | 5 |
| Zhang, X | 1 |
| Liu, H | 3 |
| Qiang, X | 4 |
| Li, Y | 2 |
| Tan, Z | 4 |
| Deng, Y | 5 |
| Tian, C | 2 |
| Yang, Z | 2 |
| Li, W | 1 |
| He, Y | 2 |
| Ye, C | 2 |
| Yu, G | 1 |
| Liu, Z | 1 |
| Zhang, L | 1 |
| Mathew, B | 1 |
| Lu, L | 1 |
| Zheng, X | 1 |
| Wang, S | 1 |
| Tang, C | 1 |
| Yao, G | 1 |
| Zeng, J | 1 |
| Ge, S | 1 |
| Wen, H | 1 |
| Xu, M | 1 |
| Guyatt, G | 1 |
| Xu, N | 1 |
| Wong, LR | 1 |
| Ho, PC | 1 |
| Al-Azzawi, S | 1 |
| Masheta, D | 1 |
| Guildford, AL | 1 |
| Phillips, G | 1 |
| Santin, M | 1 |
| Tiozzo Fasiolo, L | 1 |
| Manniello, MD | 1 |
| Bortolotti, F | 1 |
| Buttini, F | 1 |
| Rossi, A | 1 |
| Sonvico, F | 1 |
| Colombo, P | 1 |
| Valsami, G | 1 |
| Colombo, G | 1 |
| Russo, P | 1 |
| Mu, C | 1 |
| Dave, N | 1 |
| Hu, J | 1 |
| Desai, P | 1 |
| Pauletti, G | 1 |
| Bai, S | 1 |
| Hao, J | 1 |
| Sivilia, S | 4 |
| Lorenzini, L | 5 |
| Giuliani, A | 5 |
| Gusciglio, M | 3 |
| Fernandez, M | 2 |
| Baldassarro, VA | 3 |
| Mangano, C | 3 |
| Ferraro, L | 3 |
| Pietrini, V | 3 |
| Baroc, MF | 2 |
| Viscomi, AR | 2 |
| Ottonello, S | 2 |
| Calzà, L | 7 |
| Giardino, L | 5 |
| Alessandri, M | 1 |
| Torricella, R | 1 |
| Sozio, P | 1 |
| Marinelli, L | 2 |
| Cacciatore, I | 2 |
| Fontana, A | 1 |
| Türkez, H | 2 |
| Giorgioni, G | 1 |
| Ambrosini, D | 1 |
| Barbato, F | 1 |
| Grumetto, L | 1 |
| Pacella, S | 1 |
| Cataldi, A | 1 |
| Di Stefano, A | 2 |
| Aytan, N | 2 |
| Choi, JK | 2 |
| Carreras, I | 2 |
| Kowall, NW | 2 |
| Jenkins, BG | 2 |
| Dedeoglu, A | 2 |
| McKee, AC | 1 |
| Lehrer, S | 1 |
| Beggiato, S | 2 |
| Antonelli, T | 2 |
| Asakura, K | 1 |
| Hamasaki, T | 1 |
| Sugimoto, T | 1 |
| Hayashi, K | 1 |
| Evans, SR | 1 |
| Sozu, T | 1 |
| Branca, C | 2 |
| Sarnico, I | 1 |
| Ruotolo, R | 1 |
| Lanzillotta, A | 3 |
| Benarese, M | 2 |
| Porrini, V | 2 |
| Pizzi, M | 3 |
| Parrella, E | 1 |
| Flaibani, R | 1 |
| Spano, PF | 1 |
| Muntimadugu, E | 1 |
| Dhommati, R | 1 |
| Jain, A | 1 |
| Challa, VG | 1 |
| Shaheen, M | 1 |
| Khan, W | 1 |
| Fornasari, E | 1 |
| Cerasa, LS | 1 |
| Eusepi, P | 1 |
| Pomilio, C | 1 |
| Reale, M | 1 |
| D'Angelo, C | 1 |
| Costantini, E | 1 |
| Salloway, S | 2 |
| Hutter-Paier, B | 1 |
| Volta, R | 2 |
| Windisch, M | 1 |
| Hendrix, SB | 2 |
| Wilcock, GK | 2 |
| Green, RC | 1 |
| Schneider, LS | 1 |
| Amato, DA | 1 |
| Beelen, AP | 1 |
| Wilcock, G | 1 |
| Swabb, EA | 2 |
| Zavitz, KH | 3 |
| Montine, TJ | 1 |
| Larson, EB | 1 |
| D'Arrigo, A | 2 |
| Leon, A | 2 |
| Vellas, B | 1 |
| Wan, HI | 1 |
| Jacobsen, JS | 1 |
| Rutkowski, JL | 1 |
| Feuerstein, GZ | 1 |
| Shitaka, Y | 1 |
| Mitani, Y | 1 |
| Nagakura, A | 1 |
| Miyake, A | 1 |
| Matsuoka, N | 1 |
| Shoji, M | 1 |
| Holtzman, JL | 1 |
| van Groen, T | 2 |
| Miettinen, P | 1 |
| Kadish, I | 2 |
| Smith, KD | 1 |
| Paylor, R | 1 |
| Pautler, RG | 1 |
| Panza, F | 1 |
| Frisardi, V | 1 |
| Solfrizzi, V | 1 |
| Logroscino, G | 1 |
| Santamato, A | 1 |
| Greco, A | 1 |
| Seripa, D | 1 |
| Pilotto, A | 1 |
| Xia, W | 1 |
| Wong, ST | 1 |
| Hanlon, E | 1 |
| Morin, P | 1 |
| Iwai, A | 1 |
| Shankle, WR | 1 |
| Hara, J | 1 |
| Mangrola, T | 1 |
| Hendrix, S | 1 |
| Alva, G | 1 |
| Lee, MD | 1 |
| Eriksen, JL | 2 |
| Sagi, SA | 1 |
| Smith, TE | 1 |
| Weggen, S | 1 |
| Das, P | 1 |
| McLendon, DC | 1 |
| Ozols, VV | 1 |
| Jessing, KW | 1 |
| Koo, EH | 2 |
| Golde, TE | 2 |
| Wilcock, DM | 2 |
| Munireddy, SK | 1 |
| Rosenthal, A | 1 |
| Ugen, KE | 1 |
| Gordon, MN | 3 |
| Morgan, D | 4 |
| Scatena, R | 1 |
| Gasparini, L | 1 |
| Ongini, E | 1 |
| Wilcock, D | 1 |
| Townsend, KP | 1 |
| Praticò, D | 1 |
| Stock, N | 1 |
| Munoz, B | 1 |
| Wrigley, JD | 1 |
| Shearman, MS | 1 |
| Beher, D | 1 |
| Peachey, J | 1 |
| Williamson, TL | 1 |
| Bain, G | 1 |
| Chen, W | 1 |
| Jiang, X | 1 |
| St-Jacques, R | 1 |
| Prasit, P | 1 |
| Jantzen, PT | 2 |
| Li, Q | 1 |
| Geerts, H | 1 |
| Kukar, T | 1 |
| Prescott, S | 1 |
| Holloway, V | 1 |
| Murphy, MP | 1 |
| Nicolle, MM | 1 |
| Colavito, D | 1 |
| Dalle Carbonare, M | 1 |
| Serneels, L | 1 |
| De Strooper, B | 1 |
| Moreno, H | 1 |
| Wu, WE | 1 |
| Lee, T | 1 |
| Brickman, A | 1 |
| Mayeux, R | 1 |
| Brown, TR | 1 |
| Small, SA | 1 |
| Pignatello, R | 1 |
| Pantò, V | 1 |
| Salmaso, S | 1 |
| Bersani, S | 1 |
| Pistarà, V | 1 |
| Kepe, V | 1 |
| Barrio, JR | 1 |
| Puglisi, G | 1 |
| Aisen, PS | 1 |
| Black, SE | 1 |
| Laughlin, MA | 1 |
| Connor, KE | 1 |
| DiCarlo, G | 1 |
| Wenk, GL | 1 |
| Wallace, JL | 1 |
| Rojiani, AM | 1 |
| Coppola, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252] | Phase 1 | 84 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type[NCT00105547] | Phase 3 | 1,600 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| A Phase 1b, 12-Month, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Salsalate in Patients With Mild to Moderate Alzheimer's Disease[NCT03277573] | Phase 1 | 40 participants (Anticipated) | Interventional | 2017-07-21 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 reviews available for flurbiprofen and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
γ-Secretase modulators as potential disease modifying anti-Alzheimer's drugs.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Ant | 2011 |
Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment.
Topics: Acetylcholinesterase; Alzheimer Disease; Chalcones; Drug Approval; Drug Design; Enzyme Inhibitors; F | 2020 |
Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis.
Topics: Acitretin; Alanine; Alzheimer Disease; Amyloid beta-Peptides; Antibodies, Monoclonal, Humanized; Anx | 2020 |
From the multifactorial nature of Alzheimer`s disease to multitarget therapy: the contribution of the translational approach.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Anti-Inflammatory Agents; Cyclopro | 2013 |
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor | 2010 |
[Drug therapy for Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Cholinesterase In | 2010 |
Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Az | 2011 |
γ-Secretase modulator in Alzheimer's disease: shifting the end.
Topics: Alanine; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Az | 2012 |
[Gamma-secretase inhibitors and modulators].
Topics: Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Azepines; Flurbiprofen; Humans | 2011 |
Nitroflurbiprofen (NicOx).
Topics: Alzheimer Disease; Animals; Arthritis; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Flurbipr | 2004 |
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Flurbip | 2005 |
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Animals, Genetically Modified; Anti-Inflammator | 2005 |
Improving the diagnosis and treatment of Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Cho | 2006 |
Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials, Phase I as Top | 2007 |
2 trials available for flurbiprofen and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amylo | 2009 |
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secreta | 2008 |
51 other studies available for flurbiprofen and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of beta-amyloid(1)(-)(42) secretion.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2005 |
NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold.
Topics: Acids; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor P | 2011 |
Design, synthesis and evaluation of tacrine-flurbiprofen-nitrate trihybrids as novel anti-Alzheimer's disease agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cere | 2013 |
Design, synthesis and evaluation of 4'-OH-flurbiprofen-chalcone hybrids as potential multifunctional agents for Alzheimer's disease treatment.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Blood-Brain Barrier; Cell Line; Cell Surviva | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2018 |
Discovery of 4'-OH-flurbiprofen Mannich base derivatives as potential Alzheimer's disease treatment with multiple inhibitory activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Blood-Brain Barrier; Cell Line; Cho | 2019 |
Design, synthesis and evaluation of flurbiprofen-clioquinol hybrids as multitarget-directed ligands against Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Clioquinol; Drug Discovery; Flurbiprofen; Humans; Ligands; | 2020 |
Flurbiprofen-chalcone hybrid Mannich base derivatives as balanced multifunctional agents against Alzheimer's disease: Design, synthesis and biological evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Chalcone; Cholinesterase Inhibitors; | 2020 |
Role of serum albumin as a nanoparticulate carrier for nose-to-brain delivery of R-flurbiprofen: implications for the treatment of Alzheimer's disease.
Topics: Administration, Intranasal; Administration, Oral; Alzheimer Disease; Animals; Brain; CHO Cells; Cric | 2018 |
Dendrimeric Poly(Epsilon-Lysine) Delivery Systems for the Enhanced Permeability of Flurbiprofen across the Blood-Brain Barrier in Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Blood-Brain Barrier; Cell Line; Ce | 2018 |
Anti-inflammatory flurbiprofen nasal powders for nose-to-brain delivery in Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bra | 2019 |
Solubilization of flurbiprofen into aptamer-modified PEG-PLA micelles for targeted delivery to brain-derived endothelial cells in vitro.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aptamers, Nucleotide; Base Sequ | 2013 |
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim | 2013 |
New flurbiprofen derivatives: synthesis, membrane affinity and evaluation of in vitro effect on β-amyloid levels.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Astrocyt | 2013 |
Combination therapy in a transgenic model of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Drug Therapy | 2013 |
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease | 2013 |
Tacrine-flurbiprofen hybrids as multifunctional drug candidates for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cata | 2013 |
Nasal NSAIDs for Alzheimer's Disease.
Topics: Administration, Intranasal; Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen | 2014 |
CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.
Topics: Alanine; Alzheimer Disease; Animals; Azepines; Cyclopropanes; Disease Models, Animal; Extracellular | 2014 |
Sample size determination in group-sequential clinical trials with two co-primary endpoints.
Topics: Activities of Daily Living; Alzheimer Disease; Clinical Trials as Topic; Cognition; Flurbiprofen; Hu | 2014 |
Pharmacological targeting of the β-amyloid precursor protein intracellular domain.
Topics: Acetylation; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precu | 2014 |
CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Animals, Newborn; | 2015 |
Intranasal delivery of nanoparticle encapsulated tarenflurbil: A potential brain targeting strategy for Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Brain; Drug Carriers; Drug Delivery Systems; | 2016 |
Novel NSAID-Derived Drugs for the Potential Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Cel | 2016 |
Taking the next steps in the treatment of Alzheimer's disease: disease-modifying agents.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen; Hum | 2008 |
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein | 2009 |
What we have learned from the Myriad trials.
Topics: Alzheimer Disease; Flurbiprofen; Humans; Randomized Controlled Trials as Topic; Research Design | 2009 |
Why did tarenflurbil fail in Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; A | 2009 |
Late-life dementias: does this unyielding global challenge require a broader view?
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Comorbidity; | 2009 |
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V | 2010 |
Tarenflurbil for Alzheimer's disease: a "shot on goal" that missed.
Topics: Alzheimer Disease; Animals; Clinical Trials, Phase III as Topic; Flurbiprofen; Goals; Humans | 2010 |
Translational medicine lessons from flurizan's failure in Alzheimer's disease (AD) trial: Implication for future drug discovery and development for AD.
Topics: Alzheimer Disease; Animals; Biomarkers; Clinical Trials as Topic; Disease Progression; Drug Discover | 2009 |
Disease-modifying drug fails in Alzheimer's study.
Topics: Activities of Daily Living; Alzheimer Disease; Amyloid Precursor Protein Secretases; Cognition; Cogn | 2010 |
Are we prepared to deal with the Alzheimer's disease pandemic?
Topics: Aging; Alzheimer Disease; Alzheimer Vaccines; Amyloid beta-Peptides; Animals; Disease Outbreaks; Flu | 2010 |
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology.
Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anti-Infl | 2011 |
R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's disease as determined by MEMRI.
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axonal Transport; Disease Model | 2011 |
Hierarchical Bayesian cognitive processing models to analyze clinical trial data.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amnesia; Amyloid Precursor P | 2013 |
CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cerebral Cortex; Cyclopropanes; Disease Models, Animal; F | 2013 |
NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anti-Inflam | 2003 |
Arthritis medication studied for Alzheimer's disease prevention.
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen; Humans | 2004 |
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antibodies; Brain; Dexa | 2004 |
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.
Topics: Acetylcholinesterase; Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti- | 2005 |
Molecule of the month. MPC-7869 (Flurizan).
Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Flurbiprofen; Humans; Molecular | 2005 |
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N | 2006 |
Amyloid-beta vaccination, but not nitro-nonsteroidal anti-inflammatory drug treatment, increases vascular amyloid and microhemorrhage while both reduce parenchymal amyloid.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Anti-Inflammatory | 2007 |
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cyclooxyge | 2007 |
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor P | 2007 |
Imaging the Abeta-related neurotoxicity of Alzheimer disease.
Topics: Aged, 80 and over; Algorithms; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precur | 2007 |
Flurbiprofen derivatives in Alzheimer's disease: synthesis, pharmacokinetic and biological assessment of lipoamino acid prodrugs.
Topics: Alzheimer Disease; Amino Acids; Amyloid beta-Peptides; Animals; Binding, Competitive; Delayed-Action | 2008 |
Tarenflurbil: a shot on goal.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Anti-Inflam | 2008 |
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim | 2002 |